A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.

Adel Sadeq,Asim Ahmed Elnour,Farah Hamad Farah,Azza Ramadan,Mohamed A Baraka,Judit Don,Abdulla Al Amoodi,Kishore Gnana Sam,Nadia Al Mazrouei, Maisoun Alkaabi

Current reviews in clinical and experimental pharmacology（2023）

引用 2|浏览0

暂无评分

摘要

The FDA-approved indications for pitavastatin included primary dyslipidemia and mixed dyslipidemia as a supplementary therapy to dietary changes to lower total cholesterol, LDL-C, apolipoprotein B (Apo B), triglycerides (TG), and enhance HDL-C. Pitavastatin might be suitable for subjects with diabetes, ACS (reduced revascularization), metabolic syndrome, CKD, HIV, and subjects with low levels of HDL-C. We highly recommend rational individualization for the selection of statin.

查看译文

关键词

Dyslipidemia,efficacy,low-density lipoprotein cholesterol (LDL-C),pitavastatin,randomized clinical trial,safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要